参考文献/References:
[1].Gronda E,Jessup M,Iacoviello M,et al. Glucose metabolism in the kidney:neurohormonal activation and heart failure development[J]. J Am Heart Assoc,2020,9(23):e018889.
[2].国家心血管病中心.《中国心血管健康与疾病报告》2020[J]. 心肺血管病杂志,2021,40(10):1005-1009.
[3].Berliner D,Bauersachs J. Current drug therapy in chronic heart failure:the new guidelines of the European Society of Cardiology (ESC)[J]. Korean Circ J, 2017,47(5):543-554.
[4].Tsutsui H,Isobe M,Ito H,et al. JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure—Digest Version[J]. Circ J 2019,83(10):2084-2184.
[5].Go AS,Mozaffarian D,Roger VL,et al. Heart disease and stroke statistics--2014 update:a report from the American Heart Association[J]. Circulation,2014,129(3):e28-e292.
[6].Nishikimi T,Maeda N,Matsuoka H. The role of natriuretic peptides in cardioprotection[J]. Cardiovasc Res,2006,69(2):318-328.
[7].de Bold AJ,Borenstein HB,Veress AT,et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats[J]. Life Sci,1981,28(1):89-94.
[8].Newton-Cheh C,Larson MG,Vasan RS,et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure[J]. Nat Genet,2009,41(3):348-353.
[9].Gupta DK,Wang TJ. Natriuretic peptides and cardiometabolic health[J]. Circ J,2015,79(8):1647-1655.
[10].Somanna NK,Yariswamy M,Garagliano JM,et al. Aldosterone-induced cardiomyocyte growth,and fibroblast migration and proliferation are mediated by TRAF3IP2[J]. Cell Signal,2015,27(10):1928-1938.
[11].Fujita S,Shimojo N,Terasaki F,et al. Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor A cascade[J]. Heart Vessels,2013,28(5):646-657.
[12].Abassi Z,Karram T,Ellaham S,et al. Implications of the natriuretic peptide system in the pathogenesis of heart failure:diagnostic and therapeutic importance[J]. Pharmacol Ther,2004,102(3):223-241.
[13].谭令,付长庚,龙霖梓,等. 利钠肽检测在心力衰竭中的应用价值[J]. 医学综述 2021,27(24):4875-4882.
[14].Bae EH,Ma SK,Lee J,et al. Altered regulation of renal nitric oxide and atrial natriuretic peptide systems in angiotensin II-induced hypertension[J]. Regul Pept,2011,170(1-3):31-37.
[15].Potter LR,Abbey-Hosch S,Dickey DM. Natriuretic peptides,their receptors,and cyclic guanosine monophosphate-dependent signaling functions[J]. Endocr Rev,2006,27(1):47-72.
[16].Clemmer JS,Pruett WA,Hester RL,et al. Preeminent role of the cardiorenal axis in the antihypertensive response to an arteriovenous fistula:an in silico analysis[J]. Am J Physiol Heart Circ Physiol,2019,317(5):H1002-H1012.
[17].van Tassell BW,Seropian IM,Toldo S,et al. Interleukin-1β induces a reversible cardiomyopathy in the mouse[J]. Inflamm Res,2013,62(7):637-640.
[18].Buckley LF,Abbate A. Interleukin-1 blockade in cardiovascular diseases:a clinical update[J]. Eur Heart J,2018,39(22):2063-2069.
[19].Van Tassell BW,Arena RA,Toldo S,et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure[J]. PLoS One,2012,7(3):e33438.
[20].Francis GS,Bartos JA,Adatya S. Inotropes[J]. J Am Coll Cardiol,2014,63(20):2069-2078.
[21].Sager HB,Heidt T,Hulsmans M,et al. Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction[J]. Circulation,2015,132(20):1880-1890.
[22].Kiemer AK,Vollmar AM. The atrial natriuretic peptide regulates the production of inflammatory mediators in macrophages[J]. Ann Rheum Dis,2001,60(Suppl 3):iii68-iii70.
[23].Zhang W, Chancey AL, Tzeng HP,et al. The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions[J]. Circulation ,2011,124(19): 2106-2116.
[24].Higuchi Y,McTiernan CF,Frye CB,et al. Tumor necrosis factor receptors 1 and 2 differentially regulate survival,cardiac dysfunction,and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy[J]. Circulation,2004,109(15):1892-1897.
[25].Saito Y,Nakao K,Itoh H,et al. Brain natriuretic peptide is a novel cardiac hormone[J]. Biochem Biophys Res Commun 1989,158(2):360-368.
[26].Saito Y. Roles of atrial natriuretic peptide and its therapeutic use[J]. J Cardiol,2010,56(3):262-270.
[27].Hata N,Seino Y,Tsutamoto T,et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure:the PROTECT multicenter randomized controlled study[J]. Circ J,2008,72(11):1787-1793.
[28].Ambwani J,Ubhrani D,Saad R,et al. Could atrial natriuretic peptide be a useful drug therapy for high-risk patients after cardiac surgery[J]? Interact Cardiovasc Thorac Surg,2009,8(4):474-478.
[29].Mitaka C,Kudo T,Jibiki M,et al. Effects of human atrial natriuretic peptide on renal function in patients undergoing abdominal aortic aneurysm repair[J]. Crit Care Med,2008,36(3):745-751.
[30].Potter LR. Natriuretic peptide metabolism,clearance and degradation[J]. FEBS J,2011,278(11):1808-1817.
[31].Feygina EE,Katrukha AG,Semenov AG. Neutral endopeptidase (neprilysin) in therapy and diagnostics:Yin and Yang[J]. Biochemistry (Mosc),2019,84(11):1346-1358.
[32].Mills J,Vardeny O. The role of neprilysin inhibitors in cardiovascular disease[J]. Curr Heart Fail Rep,2015,12(6):389-394.
[33].Chen Y,Burnett JC Jr. Biochemistry,therapeutics,and biomarker implications of neprilysin in cardiorenal disease[J]. Clin Chem,2017,63(1):108-115.
[34].McMurray JJ,Packer M,Desai AS,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med 2014,371(11):993-1004.
[35].Velazquez EJ,Morrow DA,DeVore AD,et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure[J]. N Engl J Med,2019,380(6):539-548.
[36].Nougué H,Pezel T,Picard F,et al. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure:a mechanistic clinical study[J]. Eur J Heart Fail,2019,21(5):598-605.
[37].Ibrahim NE,McCarthy CP,Shrestha S,et al. Effect of neprilysin inhibition on various?natriuretic peptide assays[J]. J Am Coll Cardiol,2019,73(11):1273-1284.
[38].Wang TD,Tan RS,Lee HY,et al. Effects of sacubitril/valsartan (LCZ696) on natriuresis,diuresis,blood pressures,and NT-proBNP in salt-sensitive hypertension[J]. Hypertension,2017,69(1):32-41.
[39].Seferovic JP,Claggett B,Seidelmann SB,et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes:a post-hoc analysis from the PARADIGM-HF trial[J]. Lancet Diabetes Endocrinol,2017,5(5):333-340.
[40].Jordan J,Stinkens R,Jax T,et al. Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension[J]. Clin Pharmacol Ther 2017,101(2):254-263.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(12):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(12):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(12):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(12):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(12):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(12):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(12):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(12):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]